JP2024503372A5 - - Google Patents
Info
- Publication number
- JP2024503372A5 JP2024503372A5 JP2023541564A JP2023541564A JP2024503372A5 JP 2024503372 A5 JP2024503372 A5 JP 2024503372A5 JP 2023541564 A JP2023541564 A JP 2023541564A JP 2023541564 A JP2023541564 A JP 2023541564A JP 2024503372 A5 JP2024503372 A5 JP 2024503372A5
- Authority
- JP
- Japan
- Prior art keywords
- mds
- pharmaceutical composition
- composition according
- tascinimod
- risk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21152018.4 | 2021-01-18 | ||
| EP21152018 | 2021-01-18 | ||
| EP21201509.3 | 2021-10-07 | ||
| EP21201509 | 2021-10-07 | ||
| EP21205665 | 2021-10-29 | ||
| EP21205665.9 | 2021-10-29 | ||
| PCT/EP2022/050891 WO2022152902A1 (en) | 2021-01-18 | 2022-01-17 | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024503372A JP2024503372A (ja) | 2024-01-25 |
| JP2024503372A5 true JP2024503372A5 (https=) | 2025-01-16 |
| JP7837338B2 JP7837338B2 (ja) | 2026-03-30 |
Family
ID=80034981
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023541564A Active JP7837338B2 (ja) | 2021-01-18 | 2022-01-17 | 骨髄異形成症候群の処置における使用のためのタスキニモドまたはその薬学的に許容される塩 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240091215A1 (https=) |
| EP (1) | EP4277628B1 (https=) |
| JP (1) | JP7837338B2 (https=) |
| KR (1) | KR20230133317A (https=) |
| AU (1) | AU2022208424A1 (https=) |
| CA (1) | CA3204120A1 (https=) |
| ES (1) | ES3057099T3 (https=) |
| IL (1) | IL304232A (https=) |
| MX (1) | MX2023008016A (https=) |
| PL (1) | PL4277628T3 (https=) |
| WO (1) | WO2022152902A1 (https=) |
| ZA (1) | ZA202307855B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4346773T3 (pl) | 2021-05-25 | 2025-11-03 | Active Biotech Ab | Duża liczba cząstek taskwinimodu i ich zastosowanie |
| WO2024137713A1 (en) * | 2022-12-20 | 2024-06-27 | Constellation Pharmaceuticals, Inc. | Methods for treating lower risk myelodysplastic syndrome |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| US7189740B2 (en) * | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| SG186430A1 (en) | 2010-07-09 | 2013-01-30 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| EP3711484A1 (en) * | 2013-07-05 | 2020-09-23 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Soluble cd33 for treating myelodysplastic syndromes (mds) |
| KR20160136323A (ko) * | 2014-02-28 | 2016-11-29 | 인사이트 코포레이션 | 골수형성이상증후군 치료용 jak1 억제제 |
| JP6647287B2 (ja) * | 2014-09-23 | 2020-02-14 | アクティブ バイオテック エイビー | 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド |
| MX379401B (es) * | 2014-11-19 | 2025-03-11 | Active Biotech Ab | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| EA202090655A1 (ru) * | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
| JP2019127473A (ja) * | 2018-01-26 | 2019-08-01 | 学校法人同志社 | 多発性硬化症の治療及び／又は予防のための薬剤 |
-
2022
- 2022-01-17 ES ES22700096T patent/ES3057099T3/es active Active
- 2022-01-17 KR KR1020237026973A patent/KR20230133317A/ko active Pending
- 2022-01-17 EP EP22700096.5A patent/EP4277628B1/en active Active
- 2022-01-17 US US18/272,326 patent/US20240091215A1/en active Pending
- 2022-01-17 JP JP2023541564A patent/JP7837338B2/ja active Active
- 2022-01-17 PL PL22700096.5T patent/PL4277628T3/pl unknown
- 2022-01-17 MX MX2023008016A patent/MX2023008016A/es unknown
- 2022-01-17 WO PCT/EP2022/050891 patent/WO2022152902A1/en not_active Ceased
- 2022-01-17 CA CA3204120A patent/CA3204120A1/en active Pending
- 2022-01-17 AU AU2022208424A patent/AU2022208424A1/en active Pending
-
2023
- 2023-07-04 IL IL304232A patent/IL304232A/en unknown
- 2023-08-11 ZA ZA2023/07855A patent/ZA202307855B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024503372A5 (https=) | ||
| JP5667640B2 (ja) | 末梢血造血幹細胞動員剤の生産における飽和アミン化合物の使用 | |
| CN115300624A (zh) | 人参皂苷联合pd-1阻断剂在制备抗头颈鳞癌药物中的应用 | |
| CN116355846B (zh) | 一种质量稳定可控的扩增活化淋巴细胞的方法及其用于防治神经科疾病中的用途 | |
| RU2197984C1 (ru) | Способ лечения различных форм туберкулеза легких, в том числе резистентных к противотуберкулезной химиотерапии | |
| Song et al. | Autologous stem cell transplantation for systemic lupus erythematosus: report of efficacy and safety at 7 years of follow-up in 17 patients | |
| KR20230133317A (ko) | 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염 | |
| CN117159525B (zh) | Cert抑制剂在制备治疗急性髓系白血病的药物中的应用 | |
| CN112603920A (zh) | 一种中药川楝素在制备防治神经系统胶质瘤产品中的应用 | |
| US20200306302A1 (en) | Treating and inhibiting leukemia with nk-92 cells | |
| CN104434948B (zh) | 一种抗胰腺癌的药物组合物及其应用 | |
| CN1331477C (zh) | 药用纳米碳管组合物、制备方法及其应用 | |
| CN119776283B (zh) | Car-t细胞培养方法及其在肿瘤治疗中的应用 | |
| CN101283996B (zh) | 右旋蛋氨酸在制备防治辐射诱导骨髓抑制药物中的应用 | |
| CN111529539A (zh) | 一种原人参二醇在制备药物中的用途 | |
| CN104998262A (zh) | Dpp4抑制剂在防治辐射诱导骨髓抑制药物中的应用 | |
| JP2010509360A (ja) | 幹細胞移植を補助するためにＡＬＤＨｂｒ細胞を使用する方法 | |
| WO2025225578A1 (ja) | 癌治療剤 | |
| CN110215460B (zh) | 一种抗肿瘤的联用组合药物 | |
| CN105534999A (zh) | 一种用于治疗肿瘤的药物组合物及其应用 | |
| TW202608458A (zh) | 癌症治療劑 | |
| CN118252839A (zh) | 黄芪甲苷在制备促进造血干细胞归巢的药物中的用途 | |
| Chua | The Role of Stem Cells in Cancer Treatments | |
| CN107281177A (zh) | 促进造血干细胞归巢和植入的方法 | |
| Szer et al. | The addition of allogeneic peripheral blood‐derived progenitor cells to bone marrow for transplantation: results of a randomised clinical trial |